Longitudinal designs were used to examine test-retest reliability (intraclass correlation coefficient (ICC) statistics, smallest detectable difference (SDD)), and responsiveness (Pearson’s product moment correlation, ROC curve analysis; area under the ROC curve (AUC),
and minimally important change (MIC)). The DHI scores range from 0 to 100.
Results: Factor analysis revealed a different factor structure than the original DHI, resulting https://www.selleckchem.com/products/beta-nicotinamide-mononucleotide.html in dismissal of subscale scores in the DHI-N. Acceptable internal consistency was found for the total scale (alpha = 0.95). Concurrent correlations between the DHI-N and other related measures were moderate to high, highest with Vertigo Symptom Scale-short form-Norwegian version (r = 0.69), and lowest with preferred gait (r = -0.36). The DHI-N Nutlin-3a molecular weight demonstrated excellent ability to discriminate between participants with and without ‘disability’, AUC being 0.89 and best cut-off point = 29 points. Satisfactory test-retest reliability was demonstrated, and the
change for an individual should be >= 20 DHI-N points to exceed measurement error (SDD). Correlations between change scores of DHI-N and other self-report measures of functional health and symptoms were high (r = 0.50-0.57). Responsiveness of the DHI-N was excellent, AUC = 0.83, discriminating between self-perceived ‘improved’ versus ‘unchanged’
participants. The MIC was identified as 11 DHI-N points.
Conclusions: The DHI-N total scale demonstrated satisfactory measurement properties. This is the first study that has addressed and demonstrated responsiveness to important change of the DHI, and provided values of SDD and MIC to help interpret change scores.”
“Background: Paroxysmal hemicrania (PH) is a probably underreported primary headache disorder. It is characterized Selleck Ion Channel Ligand Library by repeated attacks of severe, strictly unilateral pain lasting 2 to 30 minutes localized to orbital, supraorbital, and temporal areas accompanied by ipsilateral autonomic features. The hallmark of PH is the absolute cessation of the headache with indomethacin. However, these all features may not be present in all cases and a few cases may remain unclassified according to the 2nd Edition of The International classification of Headache Disorders (ICHD-II) criteria for PH.
Methods: Twenty-two patients were included in this retrospective observation.
Results: We describe 17 patients, observed over six years, who fulfilled the ICHD-II criteria for PH. In parallel, we identified five more patients in whom one of the features of the diagnostic criteria for PH was missing. Two patients did not show any evidence of cranial autonomic feature during the attacks of headache.